Search results
Results from the WOW.Com Content Network
Antileukemic drugs, anticancer drugs that are used to treat one or more types of leukemia, include: [1] 6-Mercaptopurine; 6-Thioguanine; Arsenic trioxide; Asparaginase;
CLL is the most common type of leukemia in the UK, accounting for 38% of all leukemia cases. Approximately 3,200 people were diagnosed with the disease in 2011. [91] In Western populations, subclinical "disease" can be identified in 3.5% of normal adults, [92] and in up to 8% of individuals over the age of 70. [93]
The number of cycles given depends upon the stage of the disease and how well the patient tolerates chemotherapy. Doses may be delayed because of neutropenia, thrombocytopenia, or other side effects. [citation needed] A FDG PET scan is commonly advised following the completion of ABVD to assess response to the therapy. Interim PET (following 2 ...
Non-Hodgkin’s lymphoma (NHL) is one of the most common forms of blood cancer.1 The American Cancer Society estimates that about 81,560 people in the U.S. will be diagnosed with NHL and about ...
Malignant melanoma of the extremities, multiple myeloma, conditioning treatment before haemopoietic stem cell transplant. Myelosuppression, pulmonary fibrosis and pneumonitis (uncommon), skin necrosis (uncommon), anaphylaxis, hepatic sinusoidal obstruction syndrome and SIADH. Secondary malignancies. [16] Streptozotocin: IV, PO: Alkylates DNA.
Drug therapy may include the medications lenalidomide, antithymocyte globulin, and azacitidine. [3] Some people can be cured by chemotherapy followed by a stem-cell transplant from a donor. [3] About seven per 100,000 people are affected by MDS; about four per 100,000 people newly acquire the condition each year. [4]
[4] [5] It most commonly occurs in older adults. [2] Males are affected more often than females. [2] The five-year survival rate is about 35% in people under 60 years old and 10% in people over 60 years old. [3] Older people whose health is too poor for intensive chemotherapy have a typical survival of five to ten months. [3]
B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia Camrelizumab [22] mab: humanized: PD-1: hepatocellular carcinoma: Canakinumab [43] Ilaris: mab: human: IL-1: Y: cryopyrin-associated periodic syndrome, Yao's Syndrome, Adult Onset Still's Disease: Cantuzumab mertansine [42] mab: humanized ...